CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- FinancialsAltman Z-Score 12.08: safe zone
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
603.89MEUR696.92M · vs all stocks (USD)
Trailing P/E
21.32xvs Medical Devices peers
Revenue (TTM)
111.05MEUR128.15M · vs all stocks (USD)
Profit Margin
14.15%vs Medical Devices peers
Beta
0.8490xvs all stocks
52-Week Change
-54.18%vs all stocks
Market Capitalization
603.89MEUR696.92M · vs all stocks (USD)
Enterprise Value
333.42MEUR384.79M · vs all stocks (USD)
Trailing P/E
21.32xvs Medical Devices peers
Forward P/E
12.95xvs Medical Devices peers
PEG Ratio
-0.3398xvs Medical Devices peers
Price to Sales (TTM)
3.30xvs Medical Devices peers
Price to Book (MRQ)
2.91xvs Medical Devices peers
Enterprise to Revenue
3.00xvs Medical Devices peers
Enterprise to EBITDA
13.89xvs Medical Devices peers
Gross Margin
68.50%vs Medical Devices peers
Profit Margin
14.15%vs Medical Devices peers
Operating Margin
8.43%vs Medical Devices peers
Return on Assets (TTM)
9.17%vs Medical Devices peers
Return on Equity (TTM)
13.70%vs Medical Devices peers
Revenue (TTM)
111.05MEUR128.15M · vs all stocks (USD)
Revenue per Share (TTM)
4.16EURUpdated Jul 17, 2026Quarterly Revenue Growth
4.60%vs Medical Devices peers
Gross Profit (TTM)
77.67MEUR89.63M · vs all stocks (USD)
EBITDA (TTM)
26.10MEUR30.12M · vs all stocks (USD)
Net Income (TTM)
15.71MEUR18.13M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-40.50%vs Medical Devices peers
Operating Cash Flow (TTM)
22.14MEUR25.55M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
13.85MEUR15.98M · vs all stocks (USD)
5-Year Average Dividend Yield
1.21%vs all stocks
Payout Ratio
67.85%vs Medical Devices peers
Revenue
109.68MEURFY2025 · Dec 31, 2025Cost of Goods Sold
31.88MEURFY2025 · Dec 31, 2025Gross Profit
77.80MEURFY2025 · Dec 31, 2025Operating Income
25.41MEUR29.33M · vs all stocks (USD)
Pre-tax Income
22.83MEURFY2025 · Dec 31, 2025Income Tax Expense
5.42MEURFY2025 · Dec 31, 2025Net Income
17.41MEURFY2025 · Dec 31, 2025EBIT
23.21MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
27.70MEURFY2025 · Dec 31, 2025Research & Development
2.03MEURFY2025 · Dec 31, 2025Selling, General & Administrative
14.33MEURFY2025 · Dec 31, 2025Other Operating Expenses
3.96MEURFY2025 · Dec 31, 2025Non-operating Interest Income
143.00KEURFY2025 · Dec 31, 2025Non-operating Interest Expense
388.00KEURFY2025 · Dec 31, 2025Net Income from Continuing Operations
17.41MEURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
21.10MEURFY2025 · Dec 31, 2025Free Cash Flow
20.00MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
26.24MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
17.41MEURFY2025 · Dec 31, 2025Stock-based Compensation
344.00KEURFY2025 · Dec 31, 2025Other Non-cash Items
3.44MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.33MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.43MEURFY2025 · Dec 31, 2025Capital Expenditures
-1.10MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-3.08MEURFY2025 · Dec 31, 2025Net Acquisitions
0.00EURFY2025 · Dec 31, 2025Purchase of Investments
-1.07MEURFY2025 · Dec 31, 2025Other Investing Activity
1.00KEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.16MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-4.20MEURFY2025 · Dec 31, 2025Common Dividends Paid
-10.64MEURFY2025 · Dec 31, 2025Other Financing Charges
1.00KEURFY2025 · Dec 31, 2025Net Financing Cash Flow
-14.84MEURFY2025 · Dec 31, 2025Shares Outstanding
26.61MSharesUpdated Jul 17, 2026Float Shares
25.16MSharesUpdated Jul 17, 2026% Held by Insiders
9.65%vs all stocks
% Held by Institutions
51.43%vs all stocks
Total Cash (MRQ)
21.40MEUR24.70M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.7880EURUpdated Jul 17, 2026Total Debt (MRQ)
10.80MEUR12.46M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0921xvs Medical Devices peers
Current Ratio (MRQ)
2.27xvs Medical Devices peers
Book Value per Share (MRQ)
4.32EURUpdated Jul 17, 2026Total Assets
150.65MEUR173.86M · vs all stocks (USD)
Total Current Assets
52.83MEURFY2025 · Dec 31, 2025Total Liabilities
35.94MEURFY2025 · Dec 31, 2025Total Non-current Assets
97.82MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
10.16MEURFY2025 · Dec 31, 2025Total Current Liabilities
25.78MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
26.24MEURFY2025 · Dec 31, 2025Accounts Receivable
10.68MEURFY2025 · Dec 31, 2025Inventory
10.83MEURFY2025 · Dec 31, 2025Accounts Payable
8.39MEURFY2025 · Dec 31, 2025Short-term Debt
5.70MEURFY2025 · Dec 31, 2025Other Current Liabilities
1.18MEURFY2025 · Dec 31, 2025Long-term Debt
5.29MEURFY2025 · Dec 31, 2025Other Non-current Liabilities
455.00KEURFY2025 · Dec 31, 2025Common Stock (Book)
5.32MEURFY2025 · Dec 31, 2025Retained Earnings
59.35MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
114.70MEUR132.37M · vs all stocks (USD)
Treasury Stock
1.57MEURFY2025 · Dec 31, 202552-Week Low
12.02EURUpdated Jul 17, 202652-Week High
29.10EURUpdated Jul 17, 202652-Week Change
-54.18%vs all stocks
Beta
0.8490xvs all stocks
50-Day MA
13.11EURUpdated Jul 17, 2026200-Day MA
18.86EURUpdated Jul 17, 2026Avg 10-Day Volume
36.16KSharesUpdated Jul 17, 2026Avg 30-Day Volume
40.78KSharesUpdated Jul 17, 2026Diluted EPS (TTM)
0.5900EURUpdated Jul 17, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Goodwill-Heavy Equity
Equity looks heavy for the industry, but much of it is goodwill from past acquisitions.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 12.08: safe zoneNotable
Altman Z-Score: 12.08
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Ars Pharmaceuticals Inc
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Minsheng Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Fuan Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Omeros Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shandong Keyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Knight Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Science Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vishee Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hvsen Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
United States Lime & Minerals Inc.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Napco Security Technologies, Inc.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Catalyst Pharmaceuticals Inc.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity